Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actelion has reported that preliminary efficacy data generated in the proof of concept study evaluating bosentan (500mg bid) in metastatic melanoma (stage 4) does not support the initiation of a full clinical development program in this indication.
Subscribe to our email newsletter
The observed safety profile was consistent with earlier findings in clinical studies that led to the approval of bosentan (Tracleer 125mg bid) in pulmonary arterial hypertension (PAH).
The company will fully analyze the data generated in this study with close to 90 patients and discuss the detailed findings with key medical experts in the field. The company will also continue to evaluate the potential use of endothelin receptor antagonism in pre-clinical cancer models.